bone metastases are in the breast, prostate, lung, kidney, and thyroid. The evolution of a bone metastasis depends on the affected bone type and its location. The most common sites of bone metastases are the spine, proximal femur, pelvis, ribs, and
Catalin Cirstoiu, Bogdan Cretu, Sergiu Iordache, Mihnea Popa, Bogdan Serban, and Adrian Cursaru
Stijn E. W. Geraets, P. Koen Bos, and Johan van der Stok
However, there is no consensus in the guidelines or literature as to which types of long bone metastasis benefit from preoperative embolization in order to reduce blood loss. The primary aim of this systematic review was to identify long bone metastases
Elisa Pala, Alberto Procura, Giulia Trovarelli, Antonio Berizzi, and Pietro Ruggieri
parameters to consider when approaching a patient with bone metastasis, such as age, performance status, number and site of metastases, the free interval of disease, histotypes of the primary tumor, and expected survival ( 2 , 3 ). The treatment of long bone
Julie J. Willeumier, Yvette M. van der Linden, Michiel A.J. van de Sande, and P.D. Sander Dijkstra
for an impending fracture, and an intramedullary nail with cement in the lesion or a DF-MTP should be considered. Fig. 6 Patient with solitary bone metastasis from non small cell lung carcinoma (diagnosed and treated 4.5 years ago). Metastasis of
Miklós Szendrői, Imre Antal, Attila Szendrői, Áron Lazáry, and Péter Pál Varga
. 28 Risk factors for developing a bone metastasis were tumour size (> 5 cm), higher tumour grade, sub-type of the tumour (lobular carcinoma) and number of positive lymph nodes. For those patients with metastases in the bone, factors influencing
Morten Schultz Larsen and Hagen Schmal
. BMJ Case Rep 2017 . 23. Ota S Inoue R Shiozaki T . Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis . Breast Cancer 2017 ; 24 : 601 – 607 . 24
Sakae Tanaka
of cancer, infection, cardiovascular disease, delayed fracture healing, hypocalcaemia, or osteonecrosis of the jaw. In addition to its anti-osteoporotic function, denosumab prevents skeletal-related events in patients with bone metastasis from solid